Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CD19-specific T Cells

Home DrugsCD19-specific T Cells

CD19-specific T Cells

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS
Applicant: ATARA BIOTHERAPEUTICS INCPriority: 2019
CN
EP
US
3 publications
Humanized CD37 and bi-specific CD19-humanized CD37 CAR-T cells
Applicant: PROMAB BIOTECHNOLOGIES INCPriority: 2020
US
WO
3 publications
Specific chimeric antigen receptor T cells targeting CD19 and preparation and clinical application thereof
Applicant: NANJING KAEDI BIOTECH CO LTDPriority: 2019
CN
Polynucleotides encoding rituximab-resistant chimeric antigen receptors
Applicant: ALLOGENE THERAPEUTICS INCPriority: 2020
EP
US
3 publications
CELLS EXPRESSING ANTI-CD19 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
Applicant: ALLOGENE THERAPEUTICS INCPriority: 2023
CN
EP
WO
3 publications
MULTI-SPECIFIC ANTIGEN-BINDING PROTEIN TARGETING BCMA, CD19 AND CD3 AND USE THEREOF
Applicant: ITABMED BIOPHARMACEUTICAL SHANGHAI CO LTDPriority: 2024
WO
Construction of CAR-T cell for co-expressing IL18 through non-viral carrier and application of CAR-T cell
Applicant: HANGZHOU RONGZE BIOTECHNOLOGY CO LTDPriority: 2018
CN
TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
Applicant: NOVARTIS AGPriority: 2013
CN
EP
US
WO
11 publications